ReviewChembiochem : a European journal of chemical biology2020
Trends and Innovations in Biosensors for COVID-19 Mass Testing.
Review in Chembiochem : a European journal of chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 146 citations in OpenAlex.
- Article
- Assessment of the Effective Sensitivity of SARS-CoV-2 Sample Pooling Based on a Large-Scale Screening Experience: Retrospective Analysis.JMIR public health and surveillance · 2024Article
- Article
- Exploring Biosensors' Scientific Production and Research Patterns: A Bibliometric Analysis.Sensors (Basel, Switzerland) · 2024Review
- Rapid detection of vaccinia virus using biofunctionalized fiber-optic ball-tip biosensors.Scientific reports · 2023Article
- Photothermal Effect of Gold Nanoparticles as a Nanomedicine for Diagnosis and Therapeutics.Pharmaceutics · 2023Review
- Insight of smart biosensors for COVID-19: A review.Luminescence : the journal of biological and chemical luminescence · 2023Review
- Evolution of the newest diagnostic methods for COVID-19: a Chinese perspective.Journal of Zhejiang University. Science. B · 2023Review
- Emerging trends in point-of-care biosensing strategies for molecular architectures and antibodies of SARS-CoV-2.Biosensors & bioelectronics: X · 2023Review
- Review
- PCR-like performance of rapid test with permselective tunable nanotrap.Nature communications · 2023Article
- Numerical optimization of microfluidic biosensor detection time for the SARS-CoV-2 using the Taguchi method.Indian journal of physics and proceedings of the Indian Association for the Cultivation of Science (2004) · 2023Article
- Dual ligand-induced photoelectrochemical sensing by integrating Pt/MoSSensors and actuators. B, Chemical · 2023Article
- Emerging Methods in Biosensing of Immunoglobin G-A Review.Sensors (Basel, Switzerland) · 2023Review
- Current Technologies for Detection of COVID-19: Biosensors, Artificial Intelligence and Internet of Medical Things (IoMT): Review.Sensors (Basel, Switzerland) · 2022Review
- Pandemic driven innovation: A pilot evaluation of an alternative respiratory pathogen collection device.The American journal of emergency medicine · 2022Article
- Article
- Guiding organisational decision-making about COVID-19 asymptomatic testing in workplaces: mixed-method study to inform an ethical framework.BMC public health · 2022Article
- Sensitive SARS-CoV-2 detection in wastewaters using a carbon nanodot-amplified electrochemiluminescence immunosensor.Talanta · 2022Article
- Progress and Challenges of Point-of-Need Photonic Biosensors for the Diagnosis of COVID-19 Infections and Immunity.Biosensors · 2022Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Fast and widespread diagnosis is crucial to fighting against the outbreak of COVID-19. This work surveys the landscape of available and emerging biosensor technologies for COVID-19 testing. Molecular diagnostic assays based on quantitative reverse transcription polymerase chain reaction are used in most clinical laboratories. However, the COVID-19 pandemic has overwhelmed testing capacity and motivated the development of fast point-of-care tests and the adoption of isothermal DNA amplification. Antigenic and serological rapid tests based on lateral-flow immunoassays suffer from low sensitivity. Advanced digital systems enhance performance at the expense of speed and the need for large equipment. Emerging technologies, including CRISPR gene-editing tools, benefit from high sensitivity and specificity of molecular diagnostics and the easy use of lateral-flow assays. DNA sequencing and sample pooling strategies are highlighted to bring out the full capacity of the available biosensor technologies and accelerate mass testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.